CL2015003333A1 - Vacunas de e1e2 del vhc y métodos de uso - Google Patents

Vacunas de e1e2 del vhc y métodos de uso

Info

Publication number
CL2015003333A1
CL2015003333A1 CL2015003333A CL2015003333A CL2015003333A1 CL 2015003333 A1 CL2015003333 A1 CL 2015003333A1 CL 2015003333 A CL2015003333 A CL 2015003333A CL 2015003333 A CL2015003333 A CL 2015003333A CL 2015003333 A1 CL2015003333 A1 CL 2015003333A1
Authority
CL
Chile
Prior art keywords
vhc
vaccines
methods
Prior art date
Application number
CL2015003333A
Other languages
English (en)
Spanish (es)
Inventor
Michael Houghton
Darren Hockman
John L Law
Michael Logan
Lorne D Tyrrell
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Publication of CL2015003333A1 publication Critical patent/CL2015003333A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015003333A 2013-05-15 2015-11-13 Vacunas de e1e2 del vhc y métodos de uso CL2015003333A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361823712P 2013-05-15 2013-05-15
US201361887229P 2013-10-04 2013-10-04
PCT/IB2014/001972 WO2015132619A1 (en) 2013-05-15 2014-05-15 E1e2 hcv vaccines and methods of use

Publications (1)

Publication Number Publication Date
CL2015003333A1 true CL2015003333A1 (es) 2016-09-30

Family

ID=54054625

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003333A CL2015003333A1 (es) 2013-05-15 2015-11-13 Vacunas de e1e2 del vhc y métodos de uso

Country Status (8)

Country Link
US (3) US20210145963A9 (cg-RX-API-DMAC7.html)
EP (2) EP2996718B1 (cg-RX-API-DMAC7.html)
JP (5) JP2016520077A (cg-RX-API-DMAC7.html)
CN (2) CN112999344A (cg-RX-API-DMAC7.html)
AU (3) AU2014385320B2 (cg-RX-API-DMAC7.html)
CA (1) CA2909586C (cg-RX-API-DMAC7.html)
CL (1) CL2015003333A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015132619A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016336150B2 (en) * 2015-10-08 2023-08-10 The Governors Of The University Of Alberta Hepatitis C virus E1/E2 heterodimers and methods of producing same
AU2017332854B2 (en) * 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
US10881726B2 (en) 2016-10-11 2021-01-05 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
CA3093314A1 (en) 2018-03-16 2019-09-19 The Governors Of The University Of Alberta Hepatitis c virus peptide compositions and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996004301A2 (en) 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
CA2288374A1 (en) 1997-05-06 1998-11-12 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
CA2293489C (en) 1997-06-06 2009-09-29 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
AU766635B2 (en) 1999-09-24 2003-10-23 Smithkline Beecham Biologicals (Sa) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
JP4370161B2 (ja) * 2001-06-29 2009-11-25 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｈｃｖｅ１ｅ２ワクチン組成物
US7348011B2 (en) * 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
WO2009061739A1 (en) * 2007-11-06 2009-05-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralization of hcv
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Also Published As

Publication number Publication date
AU2014385320B2 (en) 2019-10-10
CA2909586A1 (en) 2015-09-11
AU2022200747A1 (en) 2022-02-24
CN105263517B (zh) 2021-03-26
HK1216395A1 (en) 2016-11-11
WO2015132619A1 (en) 2015-09-11
US20210145963A9 (en) 2021-05-20
EP2996718B1 (en) 2020-01-15
JP2022172244A (ja) 2022-11-15
AU2020200216A1 (en) 2020-02-06
AU2014385320A1 (en) 2015-11-12
CN112999344A (zh) 2021-06-22
CA2909586C (en) 2021-08-31
JP2019142962A (ja) 2019-08-29
JP2024156917A (ja) 2024-11-06
EP2996718A4 (en) 2017-06-21
EP2996718A1 (en) 2016-03-23
US20230098265A1 (en) 2023-03-30
JP2016520077A (ja) 2016-07-11
US20240316186A1 (en) 2024-09-26
JP2021059596A (ja) 2021-04-15
US20160067332A1 (en) 2016-03-10
EP3689375A1 (en) 2020-08-05
CN105263517A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
IL290547A (en) Antibodies and methods of use
IL280155A (en) Anti- SIGLEC-8 antibodies and methods of using them
CL2016001556A1 (es) Anticuerpos anti-cd3 y métodos de uso
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
IL251970B (en) Anti-cd79b antibodies and methods of use
CL2016002462A1 (es) Anticuerpos anti-ox40 y métodos de uso
IL242394B (en) Cenicriviroc compositions and methods of making and using the same
HUE051982T2 (hu) Anti-alfa-szinuklein antitestek és alkalmazási eljárások
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
PL3623943T3 (pl) Urządzenie przenośne i sposób ograniczania korzystania z urządzenia przenośnego
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
SMT201600069B (it) Composizioni comprendenti 15-hepe e metodi d’uso delle stesse
IL244643A0 (en) Anti-ly6e antibodies and methods of use
HUE053033T2 (hu) Hidrolázoknak ellenálló kapszidokat alkalmazó készítmények és eljárások
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
CL2016000235A1 (es) Inhibidores de rorc2 y sus métodos de uso
CR20180296A (es) ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO
CO6940375A2 (es) Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo
EP2989432C0 (en) IMAGING APPARATUS AND METHOD
DK2969005T3 (da) Attenuerede influenzavira og -vacciner
BR112016004943A2 (pt) aparelho médico e uso
DK2951208T3 (da) Anti-cd83 antistoffer og anvendelse deraf
CL2015002110A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
CL2015003333A1 (es) Vacunas de e1e2 del vhc y métodos de uso